Governance Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
750.57 ^USD	+0.61%		+0.23%	-2.76%

Apr. 15	Sanofi and Regeneron?s Dupixent approval in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria	CI
Apr. 15	Sanofi and Regeneron?S Dupixent Approves in the Eu as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria	CI

Executive Committee: Regeneron Pharmaceuticals, Inc.

Manager

Positions heldSince

Leonard Schleifer

73 year

Chief Executive Officer	1988-01-07
Founder	1988-01-07
President	1988-01-07

George Yancopoulos

66 year

Chief Tech/Sci/R&D Officer	2000-12-31
Founder	1988-01-07
President	2000-12-31

Joseph LaRosa

67 year

General Counsel	2011-09-05
Corporate Secretary	2011-09-05

Ryan Crowe

Investor Relations Contact

2021-12-31

Melissa Lozner

Compliance Officer

2021-12-31

Maya Bermingham

General Counsel

2014-12-31

Bob McCowan

Chief Tech/Sci/R&D Officer

Christopher Fenimore

55 year

Director of Finance/CFO

2024-02-04

Ned Braunstein

General Counsel

2008-12-31

Andrew Murphy

68 year

Chief Tech/Sci/R&D Officer

2018-12-31

Sally A. Paull

Human Resources Officer

2015-12-31

Mark Volpe

Comptroller/Controller/Auditor

2011-12-31

Composition of the Board of Directors: Regeneron Pharmaceuticals, Inc.

Director

CommitteesSince

George Yancopoulos

66 year

Chairman

2023-06-08

Christine Poon

73 year

Executive Committee	2006-08-31
Finance Committee Chair
Governance Committee	2024-02-05
Compensation Committee Chair	2010-11-15
Finance Committee	2011-05-04
Audit Committee	2024-02-11
Nominating Committee	2024-02-05

David Schenkein

68 year

Governance Committee	2015-04-30
Nominating Committee	2015-04-30
Compensation Committee	2023-09-07
Governance Committee Chair
Nominating Committee Chair

N. Coles

65 year

Executive Committee	2011-03-17
Audit Committee	2017-02-16
Compensation Committee	2025-04-03

George Sing

76 year

Compensation Committee	1988-01-07
Audit Committee Chair	1988-01-07

Arthur Ryan

83 year

Audit Committee	2002-12-31
Governance Committee Chair	2002-12-31

Bonnie Bassler

63 year

Governance Committee	2016-09-11
Compensation Committee	2020-07-29

Michael Brown

85 year

Governance Committee

1991-05-31

Joseph Goldstein

85 year

Governance Committee

2019-06-13

Craig Thompson

73 year

Governance Committee

2022-10-02

Huda Zoghbi

71 year

Compensation Committee

2016-09-11

Kathryn Guarini

54 year

Audit Committee

2023-09-07

Leonard Schleifer

73 year

Chairman

2023-06-08

Latest Appointments: Regeneron Pharmaceuticals, Inc.

Feb. 19	AtaiBeckley Inc. Announces Executive Changes, Effective March 9, 2026	CI
Jan. 21	Ocular Therapeutix, Inc. Appoints David W. Robinson As Global Chief Commercial Officer	CI
Jan. 08	Anavex Life Sciences Corp Appoints Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology	CI
25-05-20	PRESS DIGEST-Wall Street Journal - May 20	RE
25-04-28	Arrivent Biopharma Inc Appoints Merdad Parsey to Its Board of Directors	CI
24-07-23	BridgeBio Pharma, Inc. Announces Executive Changes	CI
24-01-31	Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024	CI

More news

Former Officers and Directors: Regeneron Pharmaceuticals, Inc.

Insider

Positions held

SinceUntil

Robert Landry

Director of Finance/CFO	2013-10-02	2024-02-04
Corporate Officer/Principal	2013-09-08	2013-10-02

Marc Tessier-Lavigne

Director/Board Member	2011-11-20	2023-08-31
Independent Dir/Board Member	2011-11-20	2023-08-31

David Weinreich

Private Equity Investor

2016-01-31

2023-07-31

P. Vagelos

Chairman

1994-12-31

2023-06-08

James Cassidy

Corporate Officer/Principal

2020-01-31

2021-07-31

Jay Markowitz

Corporate Officer/Principal

2017-01-04

2019-12-31

Neil Graham

Corporate Officer/Principal

2008-12-31

2019-12-31

Johnathan Lancaster

Chief Tech/Sci/R&D Officer

2018-12-31

Ke Andrew Yuan

Corporate Officer/Principal

2014-12-31

2018-12-31

Manisha A. Narasimhan

Investor Relations Contact

2011-08-31

2018-10-31

Phillip Gutry

Corporate Officer/Principal

2015-05-31

2018-09-30

Jesper Gromada

Corporate Officer/Principal

2012-06-30

2018-09-30

Vesna Tosic

Public Communications Contact

2018-08-31

Charles A. Baker

Director/Board Member	1989-01-31	2018-06-07
Independent Dir/Board Member	1989-01-31	2018-06-07

Robert J. Terifay

Corporate Officer/Principal

2007-02-25

2018-01-04

Peter Powchik

Corporate Officer/Principal

2006-09-30

2017-12-31

Catherine Stehman-Breen

Chief Tech/Sci/R&D Officer	2014-12-31	2017-02-28
General Counsel	2014-12-31	2017-02-28

Pamela A. Trail

Corporate Officer/Principal

2010-07-31

2017-02-28

William J. Sasiela

Corporate Officer/Principal

2009-12-31

2016-12-31

Douglas S. McCorkle

Comptroller/Controller/Auditor

1998-04-30

2016-12-30

Kevin Bailey

Private Equity Investor

1991-09-30

2015-12-31

Robert Alexander Ingram

Director/Board Member	2014-04-03	2015-11-09
Independent Dir/Board Member	2015-03-10	2015-11-09

Murray Goldberg

Chief Administrative Officer	1995-02-28	2015-03-30
Director of Finance/CFO	1995-02-28	2013-10-02
Treasurer	1995-02-28	2013-05-07

Alan Shuldiner

Corporate Officer/Principal

2014-10-15

Eric M. Shooter

Director/Board Member	1988-01-07	2014-01-29
Founder	1988-01-07	2014-01-29
Independent Dir/Board Member	1988-01-07	2014-01-29
Corporate Officer/Principal	1988-01-07	2009-09-01

Hala Mirza

Public Communications Contact

2013-12-31

Julie Clark

Corporate Officer/Principal

2011-04-30

2012-09-30

Carrie Brownstein

Corporate Officer/Principal

2012-07-31

Jim Tripp

Director/Board Member

2006-12-31

2011-12-31

Daniel Brims

Corporate Officer/Principal

2011-07-30

Stuart A. Kolinski

General Counsel	2000-08-31	-
Corporate Secretary	2000-08-31	-

Michael Aberman

Investor Relations Contact

2010-03-22

Randall G. Rupp

Corporate Officer/Principal

1991-06-30

2008-04-01

Beth Levine

Compliance Officer	2007-12-31	2022-08-31
Corporate Officer/Principal	2007-12-31	-

Imogene Dunn

Corporate Officer/Principal

2002-12-31

2007-12-31

Alain Thibault

Chief Tech/Sci/R&D Officer	2009-09-01	2011-12-13
Corporate Officer/Principal	2007-02-25	2009-09-01

Michael E. Faerm

Corporate Officer/Principal

2004-09-30

Merdad Parsey

Chief Tech/Sci/R&D Officer

2001-12-31

2003-12-31

Kremena Simitchieva

Sales & Marketing

2003-12-31

Hao Zhou

Chief Tech/Sci/R&D Officer

2001-12-30

Fred Middleton

Director/Board Member	1987-12-31	2000-12-31
Director of Finance/CFO	1987-12-31	2000-12-31

William G. Roberts

Chief Tech/Sci/R&D Officer	1999-04-30	-
General Counsel	1999-04-30	-

Denny Lanfear

Corporate Officer/Principal

1990-12-31

1998-12-31

Prasad Inampudi

Corporate Officer/Principal

1998-12-30

Hans-Peter Guler

Corporate Officer/Principal

1998-03-31

Patrice Gilooly

Chief Operating Officer

1997-12-31

Ronald M. Lindsay

Corporate Officer/Principal

1996-12-31

Peter S. DiStefano

Corporate Officer/Principal

1990-12-31

1996-12-31

Gerald Underwood

Corporate Officer/Principal

1994-12-31

Christopher Chapman

Chief Tech/Sci/R&D Officer

1991-12-31

1993-12-31

Stephen Squinto

Corporate Officer/Principal

1988-12-31

1991-12-31

Neil Stahl

Chief Tech/Sci/R&D Officer	2014-12-31	-
Corporate Officer/Principal	1990-12-31	2014-12-31

Alfred G. Gilman

Director/Board Member	1988-01-07	-
Founder	1988-01-07	-
Independent Dir/Board Member	1988-01-07	-
Corporate Officer/Principal	1988-01-07	2009-09-01

Robert Lisicki

Corporate Officer/Principal

Carrie Murray

Corporate Officer/Principal

Justin Holko

Investor Relations Contact

Joseph Ricculli

Public Communications Contact

Sean Stevens

Corporate Officer/Principal

Brendan Classon

Corporate Officer/Principal

Christian Rommel

Chief Tech/Sci/R&D Officer	-	-
Corporate Officer/Principal	-	-

Matt I. Hermann

Corporate Officer/Principal

Charles Poole

Public Communications Contact

Fredric D. Price

Chief Administrative Officer	-	-
Director of Finance/CFO	-	-

Joseph Pantginis

Corporate Officer/Principal

Eric S. Furfine

Corporate Officer/Principal

Paul F. Lubetkin

General Counsel	-	-
Corporate Secretary	-	-

Paul Lin

Corporate Officer/Principal

Peter G. Dworkin

Public Communications Contact

2009-12-14

Alexandra Bowie

Public Communications Contact

Catharine E. Johnson

Corporate Officer/Principal

Steven E. Buchholz

Corporate Officer/Principal

Weng Tao

Corporate Officer/Principal

Avner Ingerman

Corporate Officer/Principal

Janet van Adelsberg

Corporate Officer/Principal

Terence E. Ryan

Corporate Officer/Principal

Potoula Gjidija

Public Communications Contact

Arleen Goldenberg

Public Communications Contact

Sondra Smyrnios

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	23
Female	7

Of which Executive Committee

Male	9
Female	3

Of which Directors

Male	12
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.

Employees

15,410

Sector

Pharmaceuticals

Calendar

Apr. 29 - Earnings release - Q1 2026

More about the company